

Simple. Swift. Sensitive.

LiquidHALLMARK® Targets by Cancer Type

LUCENCE

LUNG

FUSIONS

<i>ALK</i> #	<i>ARAF</i>	<i>BRAF</i>	<i>BRCA1</i> #1	<i>BRCA2</i> #2	<i>CDKN2A</i> #	<i>CTNNB1</i>	<i>EGFR</i> †#
<i>ERBB2</i> # (<i>HER2</i>)	<i>FGFR1</i>	<i>FGFR3</i>	<i>KEAP1</i> †	<i>KRAS</i> #	<i>MET</i> #	<i>MTOR</i>	<i>NF1</i>
<i>NFE2L2</i>	<i>NRAS</i> #	<i>NTRK1</i>	<i>NTRK3</i>	<i>PDGFRA</i> #	<i>PIK3CA</i> #	<i>PIK3R1</i>	<i>PTEN</i> #
<i>RB1</i>	<i>RET</i>	<i>RIT1</i>	<i>ROS1</i>	<i>SF3B1</i>	<i>STK11</i>	<i>TP53</i> #^	<i>U2AF1</i>
<i>ALK</i> ^{D,R}	<i>AXL-MBIP</i> ^R	<i>BRAF</i> ^R	<i>CLIP1-LTK</i> ^R	<i>EGFR</i> ^R	<i>ERBB4</i> ^R	<i>FGFR1</i> ^R	<i>FGFR3</i> ^{D,R}
<i>MET</i> ^R including exon 14 skipping	<i>NRG1</i> ^R	<i>NTRK 1/2/3</i> ^{D,R}	<i>PD-L1</i> ^D (<i>CD274</i>)	<i>RET</i> ^{D,R}	<i>ROS1</i> ^{D,R}		

BREAST

FUSIONS

<i>AKT1</i>	<i>ATM</i> #	<i>BRAF</i>	<i>BRCA1</i> #1	<i>BRCA2</i> #2	<i>CDH1</i>	<i>ERBB2</i> # (<i>HER2</i>)	<i>ESR1</i> #
<i>GATA3</i>	<i>MYC</i> #	<i>NF1</i>	<i>NTRK1</i>	<i>NTRK3</i>	<i>PIK3CA</i> #	<i>PIK3R1</i>	<i>PTEN</i> #
<i>RB1</i>	<i>RET</i>	<i>SF3B1</i>	<i>TP53</i> #^				
<i>ESR1</i> ^R	<i>FGFR1</i> ^R	<i>MYB-NFIB</i> ^R	<i>NRG1</i> ^R	<i>NTRK 1/2/3</i> ^{D,R}	<i>PD-L1</i> ^D (<i>CD274</i>)	<i>RET</i> ^{D,R}	

PROSTATE

FUSIONS

<i>AR</i> #	<i>ATM</i> #	<i>BRAF</i>	<i>BRCA1</i> #1	<i>BRCA2</i> #2	<i>KRAS</i> #	<i>MYC</i> #	<i>NTRK1</i>
<i>NTRK3</i>	<i>PIK3CA</i> #	<i>PIK3R1</i>	<i>PTEN</i> #	<i>RB1</i>	<i>RET</i>	<i>SPOP</i>	<i>TP53</i> #^
<i>AR</i> ^R V3, 4, 7 & 9 Splice Variant	<i>ERG</i> ^R	<i>ETV 1/4/5</i> ^R	<i>FLI1</i> ^R	<i>MYB-NFIB</i> ^R	<i>NTRK 1/2/3</i> ^{D,R}	<i>PD-L1</i> ^D (<i>CD274</i>)	<i>RET</i> ^{D,R}
						<i>SLC45A3</i> ^R	<i>TMPRSS2</i> ^{D,R}

OVARIAN

FUSIONS

<i>AKT1</i>	<i>APC</i>	<i>ATM</i> #	<i>BRAF</i>	<i>BRCA1</i> #1	<i>BRCA2</i> #2	<i>CTNNB1</i>	<i>ERBB2</i> # (<i>HER2</i>)
<i>FBXW7</i> #	<i>GNAS</i>	<i>KRAS</i> #	<i>MED12</i>	<i>MTOR</i>	<i>MYC</i> #	<i>NF1</i>	<i>NTRK1</i>
<i>NTRK3</i>	<i>PIK3CA</i> #	<i>PIK3R1</i>	<i>PTEN</i> #	<i>RB1</i>	<i>RET</i>	<i>TP53</i> #^	
<i>PD-L1</i> ^D (<i>CD274</i>)	<i>NTRK 1/2/3</i> ^{D,R}	<i>RET</i> ^{D,R}					

ENDOMETRIAL

FUSIONS

<i>BRAF</i>	<i>BRCA1</i> #1	<i>BRCA2</i> #2	<i>CCND1</i> #	<i>CCND2</i> #	<i>CTNNB1</i>	<i>ERBB2</i> # (<i>HER2</i>)	<i>FBXW7</i> #
<i>FGFR2</i>	<i>KRAS</i> #	<i>MTOR</i>	<i>MYC</i> #	<i>NFE2L2</i>	<i>NTRK1</i>	<i>NTRK3</i>	<i>PIK3CA</i> #
<i>PIK3R1</i>	<i>PPP2R1A</i>	<i>PTEN</i> #	<i>RET</i>	<i>TP53</i> #^			
<i>PD-L1</i> ^D (<i>CD274</i>)	<i>NTRK 1/2/3</i> ^{D,R}	<i>RET</i> ^{D,R}					

UROTHELIAL

FUSIONS

<i>BRAF</i>	<i>ERBB2</i> # (<i>HER2</i>)	<i>ERCC2</i>	<i>FGFR1</i>	<i>FGFR2</i>	<i>FGFR3</i>	<i>HRAS</i>	<i>NFE2L2</i>
<i>NTRK1</i>	<i>NTRK3</i>	<i>PIK3CA</i> #	<i>PIK3R1</i>	<i>PTEN</i> #	<i>RB1</i>	<i>RET</i>	<i>TERT</i> Promoter
<i>FGFR1</i> ^R	<i>FGFR2</i> ^{D,R}	<i>FGFR3</i> ^{D,R}	<i>NTRK 1/2/3</i> ^{D,R}	<i>PD-L1</i> ^D (<i>CD274</i>)	<i>RET</i> ^{D,R}	<i>TP53</i> #^	

COLON

FUSIONS

<i>APC</i>	<i>ATM</i> #	<i>BRAF</i>	<i>CREBBP</i>	<i>CTNNB1</i>	<i>EGFR</i> †#	<i>ERBB2</i> # (<i>HER2</i>)	<i>FBXW7</i> #
<i>JAK1</i>	<i>KRAS</i> #	<i>MLH1</i>	<i>MTOR</i>	<i>MYC</i> #	<i>NRAS</i> #	<i>NTRK1</i>	<i>NTRK3</i>
<i>PIK3CA</i> #	<i>PIK3R1</i>	<i>PTEN</i> #	<i>RAF1</i>	<i>RET</i>	<i>SMAD4</i> #^	<i>TP53</i> #^	
<i>BRAF</i> ^R	<i>NTRK 1/2/3</i> ^{D,R}	<i>PD-L1</i> ^D (<i>CD274</i>)	<i>RET</i> ^{D,R}	<i>RSPO2</i> ^R	<i>RSPO3</i> ^R		

GASTRIC & ESOPHAGEAL

FUSIONS

APC	BRAF	CDH1	CDKN2A #	CTNNB1	ERBB2# (HER2)	FBXW7 #	JAK1
KEAP1 ¹	KRAS #	MLH1	NFE2L2	NOTCH1	NTRK1	NTRK3	PIK3CA #
PD-L1 ^D (CD274)	NTRK 1/2/3 ^{D,R}	RET ^{D,R}	PIK3R1	RET	RHOA	SMAD4 #^	STK11
							TP53 #^

GIST

GASTROINTESTINAL
STROMAL TUMOR

FUSIONS

BRAF	HRAS	KIT #	KRAS #	NRAS #	NTRK1	NTRK3	PDGFRA #
NTRK 1/2/3 ^{D,R}	PD-L1 ^D (CD274)	FGFR1 ^R	RET ^{D,R}	PIK3CA #	PIK3R1	RET	TP53 #^

PANCREAS

FUSIONS

APC	BRAF	BRCA1 #1	BRCA2 #2	CDKN2A #	CTNNB1	GNAS	KRAS #
MYC #	NTRK1	NTRK3	PIK3CA #	PIK3R1	RET	SMAD4 #^	TP53 #^
NRG1 ^R	NTRK 1/2/3 ^{D,R}	PD-L1 ^D (CD274)	RET ^{D,R}				

LIVER

FUSIONS

BRAF	CCND1 #	CDKN2A #	CTNNB1	ERBB2# (HER2)	HNF1A	JAK1	KRAS #
MTOR	MYC #	NFE2L2	NRAS #	NTRK1	NTRK3	PIK3CA #	PIK3R1
DNAJB1-PRKACA ^R	NTRK 1/2/3 ^{D,R}	PD-L1 ^D (CD274)	RET ^{D,R}	PTEN #	RET	TERT Promoter	TP53 #^

BILE DUCT

FUSIONS

AKT1	BRAF	CCND1 #	CCND2 #	CDKN2A #	ERBB2# (HER2)	FGFR1	FGFR2
FGFR3	GNAS	HRAS	IDH1	IDH2	KRAS #	MET #	NRAS #
NTRK1	NTRK3	PIK3CA #	PIK3R1	PTEN #	RET	SMAD4 #^	STK11
FGFR2 ^{D,R}	FGFR3 ^{D,R}	NRG1 ^R	NTRK 1/2/3 ^{D,R}	PD-L1 ^D (CD274)	RET ^{D,R}	TP53 #^	

MELANOMA

FUSIONS

BRAF	CDKN2A #	CTNNB1	GNA11	GNAQ	KIT #	MAP2K1 (MEK1)	MAP2K2 (MEK2)
MAPK1 (ERK2)	MTOR	NF1	NRAS #	NTRK1	NTRK3	PIK3CA #	PIK3R1
PTEN #	RAF1	RET	TERT Promoter	TP53 #^			
BRAF ^R	NTRK 1/2/3 ^{D,R}	PD-L1 ^D (CD274)	RET ^{D,R}				

HEAD & NECK

FUSIONS

BRAF	CCND1 #	CDKN2A #	FBXW7 #	HRAS	KEAP1 ¹	NFE2L2	NOTCH1
NTRK1	NTRK3	PIK3CA #	PIK3R1	PTEN #	RET	TP53 #^	
CTNNB1-PLAG1 ^R	MYB-NFIB ^R	NTRK 1/2/3 ^{D,R}	PD-L1 ^D (CD274)	RET ^{D,R}			

NASO-PHARYNGEAL

FUSIONS

ATM #	BRAF	CDKN2A #	FBXW7 #	MED12	NOTCH1	NTRK1	NTRK3
PD-L1 ^D (CD274)	NTRK 1/2/3 ^{D,R}	RET ^{D,R}	PIK3CA #	PIK3R1	RET	TP53 #^	

OTHERS

FUSIONS

PAX3-FOXO1 ^R	PAX8-PPARG ^R	SSX 1/2 ^R	TFE3 ^R	THADA ^R
-------------------------	-------------------------	----------------------	-------------------	--------------------

*Targeted regions selected to maximize detection of known hotspot mutations. #: Includes detection of gene copy number changes. †Includes sequencing of EGFR kinase and extracellular domain mutations. ^Full coverage. 1: >99% coverage. 2: >98.4% coverage of coding exons. D: Fusions analyzed by ctDNA. R: Fusions analyzed by cRNA. cRNA currently investigational – provided for informational, non-diagnostic purposes only.

Customer support: +1 888 LUCENCE (582-3623) support.us@lucence.com

lucence.com

Lucence Service Laboratory | 3520 W Bayshore Rd, Palo Alto, CA94303

Lucence Health Inc.'s central laboratory is licensed by the U.S. Department of Health and Human Services' Centers for Medicare & Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 (CLIA Number: 05D2200843), and accredited by the College of American Pathologists (CAP) Laboratory Accreditation Program (CAP Number: 8822266). Refer to www.lucence.com/order-terms for Terms of Use. © 2023 Lucence Health Inc. All Rights Reserved.

Information for US medical professionals only



M1019E-US-03 May 9, 2023